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Molecular mechanisms involved in pulmonary arterial
hypertension development
Abstract
Pulmonary arterial hypertension (PAH) is an elevation in pulmonary
arterial pressure, characterized by symptoms of dyspnea, chest pain, decrease
in exercise tolerance-fatigue, syncope and, if untreated, PAH leads to right
heart failure.
In PAH, there is an imbalance between mediators of vasodilation and
vasoconstriction (e.g. nitric oxide and prostacycline – potent vasodilators,
platelet inhibitor and antimitogens are decreased in PAH, while thrombo-
xane, vasoconstrictor and platelet activator is increased in PAH, resulting in
smooth muscle hypertrophy of small vessels, adventitial and intimal prolif-
eration, and plexiform vascular lesions with vascular thrombosis). Stan-
dard diagnostic procedures for PAH include physical examination, pulmo-
nary function testing, radiographic imaging, transthoracic echocardiography,
right heart catheterization. Current drugs include synthetic prostanoids
(iloprost, epoprostenil, beraprost, treprostinil) – vasodilators and anti-
platelet agents. Phosphodiesterase-5 inhibitors decrease the breakdown of
cGMP, increasing its intracellular levels, leukotriene receptor antagonist, –
zafirlukast, decreases pulmonary arterial and venous pressure. Endothelin
receptor blockers, bosentan, decrease pulmonary vascular resistance and im-
prove results of functional tests. Other treatments are: anticoagulants, cal-
cium-channel blockers, positive airway pressure therapy for obstructive
sleep apnea, or oxygen for hypoxemia, and surgery. In conclusion, although
there are some promising drugs in therapy of PAH, there is a need to develop
new ones, together with surgical approaches, in order to increase the sur-
vival of patients with PAH. Gene and cell therapy could be expected as fu-
ture perspectives.
INTRODUCTION
Pulmonary arterial hypertension (PAH) is a disease that causes no-table morbidity and mortality and is clinically demonstrated by in-
creasing pulmonary arterial pressure (1). The incidence of PAH is
2,4–7,6/per million, with the prevalence of 15–52 patients / per million,
affecting twice as many females as males (1, 2). The epidemiological
data show that the one-, three-, and five-year survival rates were 68%,
48%, and 34%, respectively; with the progress of modern therapeutic
agents, these survival rates have improved to 86%, 69%, and 61%, re-
spectively (1).
PAH had been classified as a primary (idiopathic) or secondary form
(3). The recent World Health Organization classification of pulmo-
nary hypertension includes five categories: idiopathic PAH is the most
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prevalent form of PAH (46.2% of patients). Familial
forms of PAH caused by mutations in bone morphogenic
protein receptor-2 or activin, like kinase 1, account only
for 2.7% of cases (3). Other etiologies of PAH include:
connective tissue disorders (25.3%), congenital heart
disease (9.8%), liver disease (5.3%), human immunode-
ficiency virus infection (1.9%), and medication usage
(5.3%), pulmonary veno-occlusive disease and pulmo-
nary capillary hemangiomatosis, for less than 0.5% of
cases (3). Separate classification includes the following
diseases: pulmonary hypertension due to left-sided heart
disease, hypoxemic lung disease, and thromboembolic
disorders (4). A miscellaneous class includes sarcoidosis,
pulmonary Langerhans cell histiocytosis, lymphangio-
matosis, fibrosing mediastinitis, and other neoplasms
that compress the pulmonary arteries (4). The term PAH
comprises the primary forms as well as manifestations
resulting from other diseases, such as collagen vascular
disease, hemoglobinopathies, congenital cardiovascular
disease with systemic-to-pulmonary shunt, human im-
munodeficiency virus infection, portal hypertension,
drugs and toxin, persistent pulmonary hypertension of
the newborns and myeloproliferative disorder (4). The
symptoms of PAH are: dyspnea (60%), and fatigue (19%),
chest pain (7%), syncope (8%), lower extremity edema
(3%), and palpitations (5%). The diagnostic procedure
includes: physical examination, pulmonary function te-
sting, radiographic imaging, transthoracic echocardio-
graphy, right heart catheterization-gold standard for PAH
diagnosis and differentiation between PAH and pulmo-
nary venous hypertension (2).
The goal of this review is to present current knowl-
edge on PAH etiopathogenesis in terms of molecular
mechanisms involved, main clinical features and diag-
nosis, and to emphasize the therapeutical approach and




Development of PAH includes the complex interac-
tion of vascular effectors at all anatomic levels of the arte-
rial wall (1). Vasoconstriction, thrombosis, and inflam-
mation are major pathophysiological events leading to
vessel wall remodeling and cellular hyperproliferation.
Histologic features in PAH occur at the level of the small
peripheral pulmonary arteries. These include intimal fi-
brosis, proliferation of vascular smooth muscle, and pul-
monary arterial occlusion (4). End stage disease involves
the formation of a vessel neointima (increased deposition
of extracellular matrix and myofibroblasts) (4).
Vascular endothelial cell plays a crucial role in the reg-
ulation of the pulmonary vascular tone and in the main-
tenance of the barrier function and integrity of the alveo-
lar-capillary membrane (4). It also plays an important
role in coagulation, fibrinolysis, and angiogenesis and
participates in inflammatory response.
The endothelium is a major detector of injurious
stimuli such as: inflammation, hypoxia, toxins, shear
stress (5).
An imbalance of secreted vasoactive factors and vas-
cular remodeling via pathologic cellular processes, such
as excessive cell proliferation, vasoconstriction, and throm-
bosis, associated with more specific inflammatory re-
sponses and angiogenesis are presented in PAH (6). For
example, in PAH, there is excessive production of en-
dothelin and thromboxane, both of which are vasocon-
strictors. As a result, there is a deficit of the vasodilators,
such as prostacyclin and nitric oxide (4). In addition,
dysregulation of circulating and resident progenitor cells
may also contribute to PAH (6).
GENETIC BACKGROUND OF PAH
Some forms of PAH, as previously mentioned, have
strong genetic background, For example, mutations of
transforming growth factor-b receptor (TGF-b receptor)
superfamily are linked to PAH and likely play a causative
role in the development of disease (7). Patients with he-
reditary hemorrhagic teleangiectasia and idiopathic PAH
have specific mutations in ALK 1 or endoglin genes, en-
coding for two such members of the TGF-b receptor
super family (8). A more prevalent cohort of patients car-
ries mutations in another gene, namely, the bone mor-
phogenetic protein receptor type 2 (BMPR2) gene which
encodes for BMPR-II (8).There are more than 140 muta-
tions in BMPR2 that have been reported in patients with
familial PAH (8). The absence of BMPR 2 mutations in
some familial cohorts and in most sporadic cases indi-
cates that unidentified genetic mutations can also predis-
pose to the development of PAH (8). BMPR-II has a
complex mechanism of action, it functions as a receptor
and it participates in a number of complex intracellular
pathways that lead to regulation of gene transcription
(8). BMPR-II is expressed in the pulmonary endothe-
lium, medial smooth muscle cells, and macrophages (8).
The failure of BMP ligands to exert suppressive and pro-
tective effects on vascular smooth muscle and on the en-
dothelium leads to vascular remodeling and prolifera-
tion (9). Dysregulation of the BMP signaling pathway
may results in PAH. The fundamental analysis of the
mechanisms of the genetic predisposition to PAH is cru-
cial for interpretation of pathogenesis of PAH.
Another signaling pathway, the serotonin (5-hydroxy-
tryptamine or 5-HT) signaling pathway, has been inves-
tigated as a potential causative factor in PAH (10). Sero-
tonin acts as a vasoconstrictor and mitogen that promotes
smooth muscle hyperplasia and hyperthrophy (10). After
secretion from platelet granules, serotonin binds G-pro-
tein-coupled serotonin receptors present on pulmonary
artery smooth muscle cells (10). The receptor activation
leads to a decrease in adenylyl cyclase and cAMP, causing
an increase in contraction (10). The cell-surface seroto-
nin transporter (5-HTT) allows for transport of extra-
cellular serotonin into the cytoplasm of smooth muscle
cells, activating cellular proliferation in two ways: di-
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rectly through the action of serotonin or indirectly via po-
tential pleiotropic mechanisms (11). Also, serotonin can
inhibit BMP signaling via modulation of downstream
Smad proteins and can regulate the angiopoietin -1/Tie2
signaling pathway, another pathogenic contributor – mo-
dulating the signaling of BMPR-II via inhibition of en-
dothelial expression of one of its dimerized partners,
BMPR-I A (12). Primary PAH is characterized by in-
creased pulmonary expression of serotonin receptors and
by elevated plasma levels of serotonin (11).
OTHER FACTORS CONTRIBUTING TO
THE DEVELOPMENT OF PAH
Exogenous influences include chronic hypoxia, he-
moglobinopathies, autoimmune vascular disease, viral
infections, and congenital heart disease with systemic to
pulmonary shunt (13). Hemoglobinopathies (thalasse-
mias and sickle cell anemia) could involve PAH (13).
Hemolysis in hemoglobinopathies leads to the destruc-
tion of bioactive nitric oxide by free hemoglobin or reac-
tive oxygen species (13). An inflammatory and proli-
ferative cascade may ensue with culmination in PAH
(13). PAH could complicate autoimmune diseases, espe-
cially in the setting of the CREST (Calcinosis, usually in
fingers; Raynaud’s; loss of muscle control of the Esopha-
gus,; Sclerodactyly and Telangiectasia) a variant of lim-
ited systemic sclerosis and in mixed connective tissue dis-
eases such as systemic lupus erythematosis and rheuma-
toid arthritis. In the setting of pulmonary fibrosis and
hypoxia, inflammation and deposition of extracellular
matrix may increase vasoconstriction, proliferation, and
vessel remodeling (14).
The human immunodeficiency virus (HIV) infection
and pulmonary hypertension has been noted in approxi-
mately 0.5% of all patients with HIV infection (6–12
times higher than the general population) (15). As a re-
sult, there is an infection of smooth muscle cells with
subsequent dysregulation of proliferation, imbalance of
vascular mitogens in response to systemic HIV infection,
and endothelial injury precipitated by HIV-infected T
cells (15). Human herpes virus 8 (HHV-8) is highly as-
sociated with HIV infection, and may play a role in PAH
development with progression to plexiform lesions (15).
Increased flow through the pulmonary circulation
may also play a role in development of PAH (16). Several
congenital heart diseases with functional systemic – pul-
monary shunts, such as unrestricted ventricular septal
defects (VSD) and large patent ductus arteriosus (PDA),
lead to pulmonary vascular remodeling and PAH during
childhood (Eisenmenger’s syndrome) (16). Atrial septal
defects (ASD) with systemic – to pulmonary shunts lead
to PAH over time. Endothelial cells recognize turbulent
flow and cyclic strain leading to transduction of intra-
cellular signals and the modulation of a wide variety of
phenotypic changes (16). Laminar flow induces vaso-
protection, while turbulent flow gives rise to a pro-in-
flammatory and thrombotic state.PAH has been detected
in patients with other clinical syndromes such as idio-
pathic thrombocythemia, thrombocytosis, chronic my-
elodysplastic syndromes, portal hypertension, neonates
with failure of the fetal-to-neonatal circulatory transi-
tion, and in patients exposed to stimulants of the central
nervous system (methamphetamines and cocaine) (17).
Histopathologic processes in later stages of the disease
include thrombosis, vasoconstriction and cellular prolif-
eration (17). As a result of dysbalance of vascular ef-
fectors controlling vasodilatation and vasoconstriction,
growth suppressors and growth factors, and pro-versus
anti-thrombotic mediators, the progression of the disease
occurs (17). Nitric oxide (NO) is a potent pulmonary ar-
terial vasodilator and a direct inhibitor of platelet activa-
tion and vascular smooth muscle cell proliferation (18).
The synthesis of NO is mediated by a family of NO
synthase enzymes (NOS) (18). The endothelial isoform
(eNOS) is regulated by a number of vasoactive factors
and physiologic stimuli (hypoxia, oxidative stress and in-
flammation) (18). Carbon monoxide (CO) and hydro-
gen sulfide (H2S) are endogenously produced gaseous
vasodilators, the deficiencies of which may promote the
development of PAH (19). H2S acts as a vasodilator and
inhibitor of vessel wall proliferation which can protect
against the development of PAH in rat models (20).
Prostacyclin (PGI2), a prostanoid metabolized from en-
dogenous arachidonic acid through the cyclooxygenase
(COX) pathway, is a potent vasodilator that has been
identified as one of the most effective drugs for the treat-
ment of pulmonary arterial hypertension (21). The bio-
logical functions of prostacyclin in the pulmonary circu-
lation are mediated by a specific cell-surface receptor.
This receptor belongs to the G-protein coupled receptor
(GPCR) (22). The binding of prostacyclin to the receptor
results in activation of the G-protein and increases in-
tracellular cAMP which activates protein kinase A (22).
This produces inhibition of platelet aggregation, relax-
ation of smooth muscle, and vasodilation of pulmonary
arteries (20). Patients with PAH have decreased levels of
prostacyclin synthase in small and medium pulmonary
arteries. Another arachidonic acid metabolite, throm-
boxane A2, is involved in thrombosis, vasoconstriction
and vesel wall proliferation (20). Thromboxane A2 in-
creases vasoconstriction and activates platelets (20).
Endothelin-1 (ET-1) is expressed by pulmonary en-
dothelial cells and acts as a pulmonary arterial vaso-
constrictor and a mitogen of pulmonary smooth muscle
cells (20). As a result of its activity (vasoconstriction, re-
modeling, mitogenesis), there are significant hemody-
namic changes that lead to PAH (23). The human en-
dothelin family (ET) consists of three 21-amino acid
isopeptides: ET-1, ET-2, and ET-3 (24). Only ET-1
plays important physiological and pathophysiological role
in the regulation of vascular tone. ET-1 is released prin-
cipally from endothelial cells. Most of its effects are pa-
racrine, the most striking is its extreme and long-lasting
vasoconstrictor action (24). ET-1 can induce hypertro-
phy and hyperplasia in various cell types, fibroblast pro-
liferation, extracellular matrix production, inflammation,
and neuro-humoral stimulation (24). However, depend-
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ing on the receptor type that ET-1 binds to, it stimulates
other local mediators of vascular tone (nitric oxide (NO),
prostacyclins, and platelet-activating factors) (Figure 1).
There is a number of pathological conditions that could
elevate the levels of circulating ET-1 (atherosclerosis, ar-
terial hypertension, heart failure, PAH) (25). ET-1 acts
through two receptor subtypes – ETA and ETB. In the
vasculature, ETA receptors are located on smooth mus-
cle cells and fibroblasts, where as ETB receptors are lo-
calized on endothelial cells and, to a lesser extent, on
smooth muscle cells, fibroblasts, and macrophages. Acti-
vation of ETA receptors mediates vasoconstriction, pro-
liferation, hypertrophy, cell migration, and fibrosis, whe-
reas activation of endothelial ETB receptors stimulates
the release of potent vasodilators (NO and prostacyclin)
which exhibit anti-proliferative properties, and prevents
apoptosis (25).
Dysregulation of vasoactive intestinal peptide (VIP)
can be involved in the pathogenesis of PAH (23). VIP is
pulmonary vasodilator and it is decreased in PAH, both
in serum and lung tissue (26). Pulmonary arterial and
pulmonary vascular resistances decrease after treatment
with VIP (26).
There are some other vascular elements that could
initiate pulmonary vascular disease (dysfunction of ad-
ventitial fibroblasts, components of the extracellular ma-
trix) (5). Vascular endothelial growth factor (VEGF) is a
central growth and survival factor for the endothelial cell
and exerts a variety of physiological actions in the lungs,
where particularly high levels of VEGF are expressed
(4). VEGF acts as a cell mitogen and angiogenic factor.
Apoptosis followed by a selection of apoptosis-resistant
cells may play a pathogenic role in PAH, triggered by
VEGF receptor 2 (VEGFR-2) blockade.
The modulation of voltage-gated potassium channels
(Kv) may also represent a pathogenic mechanism of
PAH (27). Kv channels are inhibited in the smooth mus-
cle cells in the pulmonary arterial tree in response to
hypoxia (27). Depolarization leads to the opening of
voltage-gated calcium channels and the initiation of in-
tracellular signaling cascades promoting vasoconstric-
tion and proliferation and inhibiting apoptosis (227).
This activity is regulated by serotonin, nitric oxide and
thromboxane A2 (27). The Kv pathway may represent a
root of regulation in the pathogenesis of PAH.
Angiopoietin-1 is an angiogenic factor which is in-
cluded in regulation of the vascular effectors of PAH
(27). It is produced by smooth muscle cells and pericytes:
it binds the Tie2 receptor which then activates smooth
muscle migration and proliferation (27). Angiopoietin-1
can stimulate pulmonary arterial endothelial cells to se-
crete mitogenic factors (serotonin and endothelin-1) (28).
It represents a major connection between BMP and sero-
toninergic pathways.
The actions of caveolae and its protein caveolin-1
(CAV-1) may also be a possible regulatory pathway of the
development of PAH (28). Calveolae are flask-shaped
invaginations found on the surface of the plasma mem-
brane in variety of vascular cell types (pulmonary endo-
thelium, vascular smooth muscle cells, and fibroblasts)
(28). CAV-1 is depleted in plexiform lesions and muscu-
larized pulmonary arterioles from patients with PAH
(28). The pathogenesis of PAH may include severe in-
flammatory reaction mediated by interleukin-1b, trans-
forming growth factor-b1, bradykinin, monocyte chemo-
tactic protein-1, fractalkine, RANTES and leukotrienes,
among others. 5-lipoxygenase (5-LO) regulates the syn-
thesis of leukotrienes (28). Vascular-specific serine ela-
stase activity has been involved in the pathogenesis of
PAH via regulation of the remodeling response in the
extracellular matrix (28). Serine elastases are secreted
into the extracellular space to activate matrix metallo-
proteinases (MMP) and to inhibit tissue inhibitors of
MMP (TIMP) (28). Both MMP and elastases degrade
most components of the extracellular matrix, leading to
an upregulation of fibronectin and enhancement of cel-
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Figure 1. Main pathways involved in the pathophysiology of PAH (based on ref 32).
lular migration (28). This could lead to increased integ-
rin signaling with resulting expression of the glycopro-
tein tenascin C which acts with other growth factors to
enhance smooth muscle proliferation (28). Inhibitors of
elastase can induce the apoptosis of smooth muscle cells
in cell culture (28).
MODIFICATION OF MEDIATORS AND ITS
PATHWAYS IN THE THERAPY OF PAH
PAH is a complex disease which demands multi-
disciplinary and individual approach. The main focus of
PAH therapeutical approach is improvement of symp-
toms, quality of life, and clinical outcome, as well as pre-
vention of disease progression. All of them include some
lifestyle changes, such as plenty of rest, moderate activity,
smoking cessation, avoiding of use of birth control pills,
and drugs that can lower blood pressure excessively, stress
reduction, healthy diet and maintenance of healthy wei-
ght (21). Treatment of PAH can be medicamentous and
well as surgical, depending on the disease development
stage. Surgical treatment includes atrial septostomy, pul-
monary endarterectomy (in patients with chronic throm-
boembolic disease and large central clots) and lung trans-
plantation (21).
Medications include vasodilators, endothelin receptor
antagonists, PDE 5 inhibitors, sometimes high dose cal-
cium channel blockers, anticoagulants,diuretics and ox-
ygen. Current drugs include synthetic prostanoids – va-
sodilatators and antiplatelet agents (iloprost, epoprostenil,
beraprost, treprostinil) which decrease mean pulmonary
artery pressure (PAP) and increase the cardiac index in
patients with PAH, prolonging survival (21). Epopro-
stenol, a synthetic prostacyclin, iloprost and treprostinil –
synthetic analogues, are used to treat patients with PAH.
These drugs have improved circulatory hemodynamics,
breathing, exercise tolerance and survival. The inhala-
tion of these drugs can reduce pulmonary vascular pres-
sure without affecting systemic vascular pressure (22).
Prostanoids in combination with other drugs selective
for the pulmonary circulation may be a choice in PAH
therapy (22). Producing an oral prostanoid is important
in the management of PAH, because it will bridge over a
number of problems associated with intravenous and
central venous catheter use (infection, pump failure, and
catheter and pump occlusion) (22).
Phosphodiesterase-5 inhibitors, such as sidelafil, de-
crease the breakdown of cGMP, increasing intracellular
levels of this vasorelaxing agent (24).
Leukotriene receptor antagonist, zafirlukast, decrea-
ses pulmonary arterial pressure (PAP) by inhibiting the
action of leukotriens and reduces PAP and pulmonary
venous pressure, but it does not affect the systemic mean
blood pressure (24).
Endothelin receptor blockers, e.g. bosentan is an oral
nonselective or dual-endothelin receptor antagonist that
blocks both ET-A and ET-B receptors. Bosentan de-
creases pulmonary vascular resistance and improves the
results of functional tests (24). It has been established as a
first-line option for the majority of PAH patients. En-
dothelin – receptor antagonists (ETRAs) comprise
sulfonamide and non –sulfonamide agents with differ-
ent affinities for ET-receptor subtypes (Eta and ETb).
Selective ETA-receptor antagonists should be more ef-
fective in achieving this than non-selective ETA/ETB –
receptor antagonists (25). Selective ETB – receptor
blockade results in vasoconstriction and reduced blood
flow. Co-administration of selective ETA- and ETB- re-
ceptor antagonists attenuates the vasodilator response
relative to selective ETA-receptor blockade (25). Classi-
cal vasodilators cannot be used to treat PAH because of
their systemic hypotensive effects.
Anticoagulants are indicated in thrombosis in situ
(found in 25 to 50% of these patients) (25). Calcium-
-channel blockers may be effective in 5% of patients, pro-
longing survival. Other treatments include positive air-
way pressure therapy for obstructive sleep apnea, or
oxygen for hypoxemia and surgery: atrial septostomy,
pulmonary endarterectomy (in patients with chronic
thromboembolic disease and large central clots) and
lung transplantation (25). Figure 1 schematically pres-
ents main pathways involved in the pathophysiology of
PAH and the sites of action of current drugs in PAH
treatment (29, 30).
PERSPECTIVES IN THE FUTURE
THERAPY OF PAH
There are several drugs in clinical trials, e.g. the selec-
tive oral ET-A antagonists sitaxsentan and ambrisentan,
long-acting oral PDE-5 inhibitors vardenafil or tadalafil,
inhaled treprostinil, inhaled vasoactive intestinal pep-
tide, and intravenous or inhaled adrenomedullin (29).
Possible future therapy includes retinoic acid, gene
and cell therapy and modification of cell signaling path-
ways, such as Rho-kinase pathway. Retinoic acid in-
creases the transcription of prostacyclin synthase in en-
dothelial cells and retinoic acid receptors may mediate
the production of prostacyclin synthase (31). The future
of PAH treatment could involve developing agonists for
the retinoic acid receptor, or using retinoic acid to in-
crease the expression of prostacyclin synthase, and conse-
quently prostacylin production and its beneficial vaso-
dilator effects (31). Gene therapy is based on the deliv-
ered genes into the pulmonary vasculature by a viral
vector or by another fashion, with the task to produce a
desired effect on the vascular wall (31). For example,
candidates for gene therapy would be PAH patients with
mutation in ALK 1 or endoglin genes (8).
Cell therapy includes the use of cells to increase the
production of prostacyclin (32). Mesenchymal stem cells
(MSCs) that overexpress prostacyclin synthase (PGIS)
have been used in Japan to enhance engraftment and
neovascularization in a mouse model of hind-limb is-
chemia (32) and could be, according to the same princi-
ple, used in the cell therapy of PAH. Additionally, future
direction could be combination of cell and gene therapy.
A previous study has shown that NO produced by endo-
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thelial nitric oxide synthase (eNOS) decreases pulmo-
nary arterial pressure in rats. Cell based therapy with
eNOS was more effective in treating PAH than cell-
-based therapy with VEGF (32). Endothelial progenitor
cells (EPCs) are responsible for the neovascularization
of ischemic tissues and for the repair of the vascular en-
dothelial lining (32). EPCs can be damaged after the de-
velopment of hypoxia-induced PAH. Endothelial pro-
genitor cells from the umbilical cord have a high capacity
for phagocytosis and can be transduced with genes that
are therapeutic for PAH (32). Fusion – hybrid enzyme
links COX and PGIS together to specifically synthesize
prostacyclin from arachidonic acid (32). This hybrid en-
zyme increases prostacyclin production in the cells trans-
fected with a fusion enzyme gene (32). The combination
of the fusion enzyme with cell and gene therapy may re-
sult in a more effective approach to PAH treatment.
The development of new prostacyclin receptor ago-
nist drugs is one of the most crucial next steps in the
treatment of PAH. A novel agonist test drug selexipag
(2-(4(5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-
N-(methylsulfonyl)acetamide(NS-304)), alleviated vascu-
lar endothelial dysfunction, pulmonary arterial wall hyper-
trophy, and RV hypertrophy, and increased RV systolic pres-
sure (24, 33, 34).
Multiple cell types in the vascular wall (endothelial
and vascular smooth muscle cells, inflammatory cells,
and fibroblasts) rely upon the Rho-kinase signaling path-
way for homeostatic function and response to injury
(26). Rho is a guanosine – triphosphate (GTP) binding
protein that activates its downstream target, Rho-kinase
(27). When activated, rho-kinase inhibits myosin phos-
phates and conversely upregulates the ERM family of
kinase (27). Intravenous application of fasudil, a selec-
tive Rho-kinase inhibitor, can induce pulmonary vaso-
dilatation and regression of PAH in various animal mod-
els, as well as in patients with severe PAH who are
refractory to conventional therapies (27).
In conclusion, the goals of current treatment regi-
mens are to improve patients’ symptoms, to enhance ex-
ercise tolerance, to normalize hemodynamic parameters,
to improve quality of life and to extend survival. Al-
though there are some promising drugs in the therapy of
PAH, there is a need for developing new ones, together
with surgical approaches, in order to increase the sur-
vival of the patients with PAH.
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